NO300684B1 - Piperidinforbindelser, farmasöytiske preparater som inneholder dem, og anvendelse av forbindelsene for fremstilling av et medikament for behandling av psykose - Google Patents
Piperidinforbindelser, farmasöytiske preparater som inneholder dem, og anvendelse av forbindelsene for fremstilling av et medikament for behandling av psykose Download PDFInfo
- Publication number
- NO300684B1 NO300684B1 NO941965A NO941965A NO300684B1 NO 300684 B1 NO300684 B1 NO 300684B1 NO 941965 A NO941965 A NO 941965A NO 941965 A NO941965 A NO 941965A NO 300684 B1 NO300684 B1 NO 300684B1
- Authority
- NO
- Norway
- Prior art keywords
- fluoro
- piperidine
- benzisoxazol
- propyl
- mmol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 59
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 11
- 208000028017 Psychotic disease Diseases 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 7
- 150000003053 piperidines Chemical class 0.000 title description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 36
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- -1 Piperidine compound Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- GYGUWRJKLIJBQP-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzodioxol-5-yl)carbamate;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 GYGUWRJKLIJBQP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- DXWPMYXPMOCYKH-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(3,4,5-trimethoxyphenyl)carbamate Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1 DXWPMYXPMOCYKH-UHFFFAOYSA-N 0.000 claims description 2
- NBDMFWDPDDEWCU-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzothiazol-6-yl)carbamate Chemical compound C1=C2N=CSC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 NBDMFWDPDDEWCU-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- FEMMYYYIAIBEEF-UHFFFAOYSA-N 1-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propan-2-yl n-(1,3-benzodioxol-5-yl)carbamate Chemical compound C1=C2OCOC2=CC(NC(=O)OC(CN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)C)=C1 FEMMYYYIAIBEEF-UHFFFAOYSA-N 0.000 claims 1
- CVRZQGCDTFJENA-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(2,3-dihydro-1,4-benzodioxin-6-yl)carbamate Chemical compound O1CCOC2=CC(NC(=O)OCCCN3CCC(CC3)C=3C4=CC=C(C=C4ON=3)F)=CC=C21 CVRZQGCDTFJENA-UHFFFAOYSA-N 0.000 claims 1
- NVALIHMQZVFPCK-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(3,4,5-trimethoxyphenyl)carbamate Chemical group COC1=C(OC)C(OC)=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1 NVALIHMQZVFPCK-UHFFFAOYSA-N 0.000 claims 1
- LNTFLWRPWXXMFL-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(6-bromo-1,3-benzodioxol-5-yl)carbamate Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCCOC(=O)NC(C(=C1)Br)=CC2=C1OCO2 LNTFLWRPWXXMFL-UHFFFAOYSA-N 0.000 claims 1
- QILKONIUHDRLCW-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-phenylcarbamate Chemical compound N=1OC2=CC(F)=CC=C2C=1C(CC1)CCN1CCCOC(=O)NC1=CC=CC=C1 QILKONIUHDRLCW-UHFFFAOYSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- WTBQMNSYFKJCKK-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(1,3-benzothiazol-6-yl)carbamothioate Chemical compound C1=C2N=CSC2=CC(NC(=S)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 WTBQMNSYFKJCKK-UHFFFAOYSA-N 0.000 claims 1
- MDKXMXWTPVHQQC-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(2,3-dihydro-1,4-benzodioxin-6-yl)carbamothioate Chemical compound O1CCOC2=CC(NC(=S)OCCCN3CCC(CC3)C=3C4=CC=C(C=C4ON=3)F)=CC=C21 MDKXMXWTPVHQQC-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 229910001868 water Inorganic materials 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- UMNKDRAGADXPKA-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propan-1-ol Chemical compound C1CN(CCCO)CCC1C1=NOC2=CC(F)=CC=C12 UMNKDRAGADXPKA-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- WLCAJVVSNAVBSM-UHFFFAOYSA-N oxalic acid;piperidine Chemical compound C1CCNCC1.OC(=O)C(O)=O WLCAJVVSNAVBSM-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- GTTXYMVUACJZRG-UHFFFAOYSA-N 5-isocyanato-1,3-benzodioxole Chemical compound O=C=NC1=CC=C2OCOC2=C1 GTTXYMVUACJZRG-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VRBSAMVOYMTTQE-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethanol Chemical compound C1CN(CCO)CCC1C1=NOC2=CC(F)=CC=C12 VRBSAMVOYMTTQE-UHFFFAOYSA-N 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003517 fume Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 3
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (e)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 3
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 3
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 3
- CWPSRUREOSBKBQ-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole;hydrochloride Chemical compound Cl.N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 CWPSRUREOSBKBQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229960005417 ketanserin Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 3
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 2
- IEJLFJSGKCNXPW-UHFFFAOYSA-N 1-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propan-2-ol Chemical compound C1CN(CC(O)C)CCC1C1=NOC2=CC(F)=CC=C12 IEJLFJSGKCNXPW-UHFFFAOYSA-N 0.000 description 2
- NZHIDLCLGTWZRL-UHFFFAOYSA-N 1-[4-(6-fluoro-2h-indazol-3-yl)piperidin-1-yl]propan-2-ol Chemical compound C1CN(CC(O)C)CCC1C1=NNC2=CC(F)=CC=C12 NZHIDLCLGTWZRL-UHFFFAOYSA-N 0.000 description 2
- BZKOZYWGZKRTIB-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-amine Chemical compound O1CCOC2=CC(N)=CC=C21 BZKOZYWGZKRTIB-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- XEFRNCLPPFDWAC-UHFFFAOYSA-N 3,4,5-trimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- JSTUWLQAEUDQKA-UHFFFAOYSA-N 3-[4-(6-fluoro-2h-indazol-3-yl)piperidin-1-yl]propan-1-ol Chemical compound C1CN(CCCO)CCC1C1=NNC2=CC(F)=CC=C12 JSTUWLQAEUDQKA-UHFFFAOYSA-N 0.000 description 2
- MJJXWPHZDBIHIM-UHFFFAOYSA-N 5-isocyanato-1,2,3-trimethoxybenzene Chemical compound COC1=CC(N=C=O)=CC(OC)=C1OC MJJXWPHZDBIHIM-UHFFFAOYSA-N 0.000 description 2
- VQKMCZNVRYZPOW-UHFFFAOYSA-N 6-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]hexan-1-ol Chemical compound C1CN(CCCCCCO)CCC1C1=NOC2=CC(F)=CC=C12 VQKMCZNVRYZPOW-UHFFFAOYSA-N 0.000 description 2
- VBGXSEIOJQDPIE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-2h-indazole Chemical compound N=1NC2=CC(F)=CC=C2C=1C1CCNCC1 VBGXSEIOJQDPIE-UHFFFAOYSA-N 0.000 description 2
- KALNNFRLHRAJNK-UHFFFAOYSA-N 6-isothiocyanato-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=CC(N=C=S)=CC=C21 KALNNFRLHRAJNK-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940008309 acetone / ethanol Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- CRUILBNAQILVHZ-UHFFFAOYSA-N 1,2,3-trimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 description 1
- SUVCZZADQDCIEQ-UHFFFAOYSA-N 1-isocyanato-2-methoxybenzene Chemical compound COC1=CC=CC=C1N=C=O SUVCZZADQDCIEQ-UHFFFAOYSA-N 0.000 description 1
- OATRJRWJCKDPCH-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1,3-benzothiazol-5-yl)carbamate Chemical compound C1=C2SC=NC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 OATRJRWJCKDPCH-UHFFFAOYSA-N 0.000 description 1
- BTBJXOBAZNUVMO-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1,3-benzothiazol-6-yl)carbamate Chemical compound C1=C2N=CSC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 BTBJXOBAZNUVMO-UHFFFAOYSA-N 0.000 description 1
- JPWYJDOCMVVQBF-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1,3-benzoxazol-5-yl)carbamate Chemical compound C1=C2OC=NC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 JPWYJDOCMVVQBF-UHFFFAOYSA-N 0.000 description 1
- LEZOOXQOFRGIEW-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1,3-benzoxazol-6-yl)carbamate Chemical compound C1=C2N=COC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 LEZOOXQOFRGIEW-UHFFFAOYSA-N 0.000 description 1
- RWLDKAVFCRVVQT-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1h-indazol-5-yl)carbamate Chemical compound C1=C2NN=CC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 RWLDKAVFCRVVQT-UHFFFAOYSA-N 0.000 description 1
- BWYZPBZVLNFZTQ-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1h-indazol-6-yl)carbamate Chemical compound C1=C2C=NNC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 BWYZPBZVLNFZTQ-UHFFFAOYSA-N 0.000 description 1
- QVOMBFFQHFGYAQ-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1h-indol-5-yl)carbamate Chemical compound C1=C2NC=CC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 QVOMBFFQHFGYAQ-UHFFFAOYSA-N 0.000 description 1
- JMGUNWVZAMJNOL-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(1h-indol-6-yl)carbamate Chemical compound C1=C2C=CNC2=CC(NC(=O)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 JMGUNWVZAMJNOL-UHFFFAOYSA-N 0.000 description 1
- RMYYOJCAOZFNAH-UHFFFAOYSA-N 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl n-(3,4-dimethoxyphenyl)carbamate Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)OCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 RMYYOJCAOZFNAH-UHFFFAOYSA-N 0.000 description 1
- XYRDQHNCDBDNSF-UHFFFAOYSA-N 2-chloro-4-isocyanato-1-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1Cl XYRDQHNCDBDNSF-UHFFFAOYSA-N 0.000 description 1
- ZHMWZFCYUILOKB-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCC1C1=NOC2=CC(F)=CC=C12 ZHMWZFCYUILOKB-UHFFFAOYSA-N 0.000 description 1
- KYZRXZNRTTXUMF-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzothiazol-5-yl)carbamate Chemical compound C1=C2SC=NC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 KYZRXZNRTTXUMF-UHFFFAOYSA-N 0.000 description 1
- UDMONQZZVJEXOP-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzoxazol-5-yl)carbamate Chemical compound C1=C2OC=NC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 UDMONQZZVJEXOP-UHFFFAOYSA-N 0.000 description 1
- GPQXYFBRVWDWBU-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1,3-benzoxazol-6-yl)carbamate Chemical compound C1=C2N=COC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 GPQXYFBRVWDWBU-UHFFFAOYSA-N 0.000 description 1
- FPIIWIMAKPUGOR-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1h-indazol-5-yl)carbamate Chemical compound C1=C2NN=CC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 FPIIWIMAKPUGOR-UHFFFAOYSA-N 0.000 description 1
- YFZGWHDOSJCYBR-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1h-indazol-6-yl)carbamate Chemical compound C1=C2C=NNC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 YFZGWHDOSJCYBR-UHFFFAOYSA-N 0.000 description 1
- QMFIWBCNMLOVDY-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1h-indol-5-yl)carbamate Chemical compound C1=C2NC=CC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 QMFIWBCNMLOVDY-UHFFFAOYSA-N 0.000 description 1
- YPINSVAJDKKQLD-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(1h-indol-6-yl)carbamate Chemical compound C1=C2C=CNC2=CC(NC(=O)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 YPINSVAJDKKQLD-UHFFFAOYSA-N 0.000 description 1
- RVTZQECVQOHTPP-UHFFFAOYSA-N 3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl n-(3,4-dimethoxyphenyl)carbamate Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 RVTZQECVQOHTPP-UHFFFAOYSA-N 0.000 description 1
- XQVCBOLNTSUFGD-UHFFFAOYSA-N 3-chloro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1Cl XQVCBOLNTSUFGD-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- UVVSPZKAEJHDCY-UHFFFAOYSA-N 5-isothiocyanato-1,3-benzodioxole Chemical compound S=C=NC1=CC=C2OCOC2=C1 UVVSPZKAEJHDCY-UHFFFAOYSA-N 0.000 description 1
- JNTPTNNCGDAGEJ-UHFFFAOYSA-N 6-chlorohexan-1-ol Chemical compound OCCCCCCCl JNTPTNNCGDAGEJ-UHFFFAOYSA-N 0.000 description 1
- MRMGJMGHPJZSAE-UHFFFAOYSA-N 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1C1CCNCC1 MRMGJMGHPJZSAE-UHFFFAOYSA-N 0.000 description 1
- OGVYMEFCSKVNQH-UHFFFAOYSA-N 6-isocyanato-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=CC(N=C=O)=CC=C21 OGVYMEFCSKVNQH-UHFFFAOYSA-N 0.000 description 1
- DZABNZCIFXHLSQ-UHFFFAOYSA-N 6-isothiocyanato-1,3-benzothiazole Chemical compound S=C=NC1=CC=C2N=CSC2=C1 DZABNZCIFXHLSQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- RRZSXPPYUMJAOF-UHFFFAOYSA-N C(#N)N(C(O)=NOC1=CC2=C(C=C1)OCO2)C2=CC=CC=C2 Chemical compound C(#N)N(C(O)=NOC1=CC2=C(C=C1)OCO2)C2=CC=CC=C2 RRZSXPPYUMJAOF-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PBPSWRVGRHWHEW-UHFFFAOYSA-N Oxalic acid-guanidine Chemical compound NC(N)=N.OC(=O)C(O)=O PBPSWRVGRHWHEW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- HTDGNDSLZBFKPD-UHFFFAOYSA-N o-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl] n-(1,3-benzothiazol-5-yl)carbamothioate Chemical compound C1=C2SC=NC2=CC(NC(=S)OCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 HTDGNDSLZBFKPD-UHFFFAOYSA-N 0.000 description 1
- GIKOVSRXAZCPIH-UHFFFAOYSA-N o-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl] n-(3,4,5-trimethoxyphenyl)carbamothioate Chemical compound COC1=C(OC)C(OC)=CC(NC(=S)OCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1 GIKOVSRXAZCPIH-UHFFFAOYSA-N 0.000 description 1
- GRLDZYFSINPRPP-UHFFFAOYSA-N o-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl] n-(3,4-dimethoxyphenyl)carbamothioate Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)OCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 GRLDZYFSINPRPP-UHFFFAOYSA-N 0.000 description 1
- XSFXSNHHDNSQFC-UHFFFAOYSA-N o-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl] n-(3-chloro-4-methoxyphenyl)carbamothioate Chemical compound C1=C(Cl)C(OC)=CC=C1NC(=S)OCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XSFXSNHHDNSQFC-UHFFFAOYSA-N 0.000 description 1
- IZFXODXUJFIKLG-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(1,3-benzothiazol-5-yl)carbamothioate Chemical compound C1=C2SC=NC2=CC(NC(=S)OCCCN2CCC(CC2)C=2C3=CC=C(C=C3ON=2)F)=C1 IZFXODXUJFIKLG-UHFFFAOYSA-N 0.000 description 1
- KQBQFROFKSWSBD-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(3,4,5-trimethoxyphenyl)carbamothioate Chemical compound COC1=C(OC)C(OC)=CC(NC(=S)OCCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=C1 KQBQFROFKSWSBD-UHFFFAOYSA-N 0.000 description 1
- VEDGJIOINJEMAV-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(3,4-dimethoxyphenyl)carbamothioate Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 VEDGJIOINJEMAV-UHFFFAOYSA-N 0.000 description 1
- KUCBOTABJUZFJQ-UHFFFAOYSA-N o-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propyl] n-(3-chloro-4-methoxyphenyl)carbamothioate Chemical compound C1=C(Cl)C(OC)=CC=C1NC(=S)OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 KUCBOTABJUZFJQ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK9100354 | 1991-11-27 | ||
| DK71092A DK71092D0 (da) | 1992-05-27 | 1992-05-27 | Kemiske forbindelser, deres fremstilling og anvendelse |
| PCT/DK1992/000348 WO1993010742A2 (en) | 1991-11-27 | 1992-11-25 | Chemical compounds, their preparation and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO941965D0 NO941965D0 (no) | 1994-05-26 |
| NO941965L NO941965L (no) | 1994-07-26 |
| NO300684B1 true NO300684B1 (no) | 1997-07-07 |
Family
ID=8096649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO941965A NO300684B1 (no) | 1991-11-27 | 1994-05-26 | Piperidinforbindelser, farmasöytiske preparater som inneholder dem, og anvendelse av forbindelsene for fremstilling av et medikament for behandling av psykose |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0679085A1 (xx) |
| CA (1) | CA2117304A1 (xx) |
| DK (1) | DK71092D0 (xx) |
| IL (1) | IL103845A (xx) |
| NO (1) | NO300684B1 (xx) |
-
1992
- 1992-05-27 DK DK71092A patent/DK71092D0/da not_active Application Discontinuation
- 1992-11-23 IL IL10384592A patent/IL103845A/xx not_active IP Right Cessation
- 1992-11-25 CA CA002117304A patent/CA2117304A1/en not_active Abandoned
- 1992-11-25 EP EP92924586A patent/EP0679085A1/en not_active Withdrawn
-
1994
- 1994-05-26 NO NO941965A patent/NO300684B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL103845A (en) | 1997-02-18 |
| CA2117304A1 (en) | 1993-06-10 |
| DK71092D0 (da) | 1992-05-27 |
| NO941965L (no) | 1994-07-26 |
| NO941965D0 (no) | 1994-05-26 |
| EP0679085A1 (en) | 1995-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69922186T2 (de) | 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung | |
| JP2941950B2 (ja) | 或る種の４−アミノメチル−２−置換イミダゾール誘導体および２−アミノメチル−４−置換イミダゾール誘導体；新規な種類のドーパミン リセプタ亜型特異性リガンド | |
| AU715266B2 (en) | New 3-(piperid-4-YL)-1,2-benzisoxazole and 3-piperazin-4-YL)-1,2-benzisoxazole compounds, processes for their preparation and pharmaceutical compositions containing them | |
| US7247725B2 (en) | Gamma-aminoamide modulators of chemokine receptor activity | |
| EA001323B1 (ru) | 4-замещенные аналоги пиперидина и их использование в качестве подтип-селективных антагонистов рецепторов nmda | |
| HU198036B (en) | Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them | |
| PL192397B1 (pl) | Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna | |
| JP2002541103A (ja) | ピロリジン系ケモカイン受容体活性調節剤 | |
| JP2001508798A (ja) | ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類 | |
| JP2009532381A (ja) | 二環式ベンズイミダゾール化合物、および代謝型グルタミン酸受容体増強剤としての該化合物の使用 | |
| JP2002541104A (ja) | ピロリジン系ケモカイン受容体活性調節剤 | |
| AU2003284165A1 (en) | Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity | |
| NZ245260A (en) | Piperidine derivatives, preparation and pharmaceutical compositions thereof | |
| EP1558576A2 (en) | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | |
| US7550486B2 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
| DE69819903T2 (de) | Bicyclische verbindungen als liganden der 5-ht1 rezeptoren | |
| JP3803268B2 (ja) | アザビシクロアルカン誘導体とその治療的使用 | |
| JP2011526293A (ja) | ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体 | |
| IE862636L (en) | Diphenyl piperidines | |
| US5378714A (en) | Antipsychotic piperidine derivatives | |
| CA2574158A1 (en) | New benzoyl urea derivatives | |
| WO1994027991A1 (en) | Piperidine derivatives, their preparation and use | |
| AU682889B2 (en) | Imidazolone and oxazolone derivatives as dopamine antagonists | |
| NO300684B1 (no) | Piperidinforbindelser, farmasöytiske preparater som inneholder dem, og anvendelse av forbindelsene for fremstilling av et medikament for behandling av psykose | |
| JP2003502315A (ja) | ケモカインレセプター活性のｎ−シクロペンチルモジュレーター |